Skip Navigation

Receive this page by email each issue: [Sign up for eTOCs]

Contents: Volume 29, Supplement A, 1992   [Index by Author] 


Down Other Departments
Down Articles


[Search ALL Issues]

Front Matter (PDF) | Back Matter (PDF)

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.

Other Departments Back

Robert C. Spencer, Erwin M. Brown, and Jeremy M. T. Hamilton-Miller
Preface
J. Antimicrob. Chemother. 1992 29: iii; doi:10.1093/jac/29.suppl_A.iii [PDF] [Request Permissions]  

Articles Back

Robert E.W. Hancock and Francis Bellido
Factors involved in the enhanced efficacy against Gram-negative bacteria of fourth generation cephalosporins
J. Antimicrob. Chemother. 1992 29: 1-6; doi:10.1093/jac/29.suppl_A.1 [Abstract] [PDF] [Request Permissions]  

V. Schäfer, P. M. Shah, H. W. Doerr, M. Ziemen, S. Hellwich, G. Seibert, and Study Group
In-vitro activity of cefpirome against isolates from patients with urinary tract, lower respiratory tract and wound infections
J. Antimicrob. Chemother. 1992 29: 7-12; doi:10.1093/jac/29.suppl_A.7 [Abstract] [PDF] [Request Permissions]  

M. Limbert, G. Seibert, I. Winkler, D. Isert, N. Klesel, A. Markus, and E. Schrinner
Antibacterial activity in vitro of cefpirome against clinical isolates causing sexually transmitted diseases
J. Antimicrob. Chemother. 1992 29: 13-17; doi:10.1093/jac/29.suppl_A.13 [Abstract] [PDF] [Request Permissions]  

William R. Jarvis and William J. Martone
Predominant pathogens in hospital infections
J. Antimicrob. Chemother. 1992 29: 19-24; doi:10.1093/jac/29.suppl_A.19 [Abstract] [PDF] [Request Permissions]  

G. Seibert, D. Isert, N. Klesel, M. Limbert, A. Markus, and E. Schrinner
The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus
J. Antimicrob. Chemother. 1992 29: 25-30; doi:10.1093/jac/29.suppl_A.25 [Abstract] [PDF] [Request Permissions]  

D. Isert, N. Klesel, M. Limbert, A. Markus, G. Seibert, and E. Schrinner
Pharmacokinetics of cefpirome administered intravenously or intramuscularly to rats and dogs
J. Antimicrob. Chemother. 1992 29: 31-37; doi:10.1093/jac/29.suppl_A.31 [Abstract] [PDF] [Request Permissions]  

M.S. Rouse, B.M. Tallan, N.K. Henry, J. M. Steckelberg, and W. R. Wilson
Animal models as predictors of outcome of therapy with broad spectrum cephalosporins
J. Antimicrob. Chemother. 1992 29: 39-45; doi:10.1093/jac/29.suppl_A.39 [Abstract] [PDF] [Request Permissions]  

Howard B. Lassman, John W. Hubbard, Bee-Lian Chen, and Surendra K. Puri
Lack of interaction between cefpirome and alcohol
J. Antimicrob. Chemother. 1992 29: 47-50; doi:10.1093/jac/29.suppl_A.47 [Abstract] [PDF] [Request Permissions]  

David E. Nix, John H. Wilton, Norma Velasquez, James L. Budny, Howard B. Lassman, Patricia Mitchell, Kishore Divan, and Jerome J. Schentag
Cerebrospinal fluid penetration of cefpirome in patients with non-inflamed meninges
J. Antimicrob. Chemother. 1992 29: 51-57; doi:10.1093/jac/29.suppl_A.51 [Abstract] [PDF] [Request Permissions]  

M. Wolff, P. Chavanet, A. Kazmierczak, A. Pechinot, C. Dematons, H. Portier, and B. Lenfant
Diffusion of cefpirome into the cerebrospinal fluid of patients with purulent meningitis
J. Antimicrob. Chemother. 1992 29: 59-62; doi:10.1093/jac/29.suppl_A.59 [Abstract] [PDF] [Request Permissions]  

B. H. Meyer, F.O. Muller, H. G. Luus, B. Drees, H. J. Röthig, M. Badian, and H. G. Eckert
Safety, tolerance and pharmacokinetics of cefpirome administered intramuscularly to healthy subjects
J. Antimicrob. Chemother. 1992 29: 63-70; doi:10.1093/jac/29.suppl_A.63 [Abstract] [PDF] [Request Permissions]  

H. H. Donaubauer and D. Mayer
Toxicity of cefpirome: an overview
J. Antimicrob. Chemother. 1992 29: 71-73; doi:10.1093/jac/29.suppl_A.71 [Abstract] [PDF] [Request Permissions]  

P. M. Shah, V. Schäfer, M. Ziemen, S. Krauskopf, and Microbiological and Clinical Study Groups
Comparison of clinical response to cefpirome treatment and minimum inhibitory concentration of causative isolates
J. Antimicrob. Chemother. 1992 29: 75-80; doi:10.1093/jac/29.suppl_A.75 [Abstract] [PDF] [Request Permissions]  

H. Knothe, V. Schäfer, A. Sammann, M. Badian, and P. M. Shah
Influence of cefpirome on pharyngeal and faecal flora after single and multiple intravenous administrations of cefpirome to healthy volunteers
J. Antimicrob. Chemother. 1992 29: 81-86; doi:10.1093/jac/29.suppl_A.81 [Abstract] [PDF] [Request Permissions]  

C. Carbon and Cefpirome Study Group
Prospective randomized phase II study of intravenous cefpirome 1g or 2g bd in the treatment of hospitalized patients with different infections
J. Antimicrob. Chemother. 1992 29: 87-94; doi:10.1093/jac/29.suppl_A.87 [Abstract] [PDF] [Request Permissions]  

Study Group
Cefpirome versus ceftazidime in the treatment of urinary tract infections
J. Antimicrob. Chemother. 1992 29: 95-104; doi:10.1093/jac/29.suppl_A.95 [Abstract] [PDF] [Request Permissions]  

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.